ClinVar Miner

Submissions for variant NM_001126049.1(KLLN):c.-898G>A (rs538728843)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000201312 SCV000604971 likely benign not specified 2016-12-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV000115555 SCV000185343 uncertain significance Hereditary cancer-predisposing syndrome 2013-12-18 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000586614 SCV000780347 likely benign not provided 2018-02-28 criteria provided, single submitter clinical testing
ClinGen PTEN Variant Curation Expert Panel RCV000229583 SCV000886872 likely benign PTEN hamartoma tumor syndrome 2018-11-28 reviewed by expert panel curation PTEN c.-1084C>T (NC_000010.10:g.89623142C>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the "PTEN ACMG Specifications Summary" document (assertion method column). BS1: Allele frequency of 0.0025 (0.25%, 38/14,966 alleles) in the European subpopulation of the gnomAD cohort. (PMID 27535533) BP2: At least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants. (internal laboratory contributor(s) SCV000149464.4) BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (PMID 27884173, internal laboratory contributor(s) SCV000149464.4, SCV000185343.1)
Counsyl RCV000662713 SCV000785463 likely benign Cowden syndrome 1 2017-08-14 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000201312 SCV000860984 benign not specified 2018-04-24 criteria provided, single submitter clinical testing
GeneDx RCV000201312 SCV000149464 likely benign not specified 2015-05-07 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. This variant was found in HIBR-PALB2-HEREDIC,BR-OV-HEREDIC,BR-GUIDE-HEREDIC,HEREDICANCER,PTEN-HEREDIC,ALACARTE-HEREDIC,MACRO-BRAIN,HIRISK-BR-HEREDIC,COLO-HEREDIC,ENDOM-HEREDIC,COLYNCH-HEREDICV3-REST,COLOV2-HEREDIC,PTEN,MODRISK-HEREDIC
Integrated Genetics/Laboratory Corporation of America RCV000586614 SCV000696525 benign not provided 2017-02-09 criteria provided, single submitter clinical testing Variant summary: The PTEN variant c.-1084C>T (also known as c.-1085C>T) involves the alteration of a non-conserved nucleotide in the 5'UTR region. One in silico tool predicts a benign outcome for this variant. This variant was found in 28/5008 control chromosomes, predominantly observed in South Asians at a frequency of 0.0163599 (16/978). This frequency greatly exceeds the estimated maximal expected allele frequency of a pathogenic PTEN variant (0.0000063), suggesting this is likely a benign polymorphism found primarily in the populations of origin. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign/benign. Taken together, this variant is classified as benign.
Invitae RCV000229583 SCV000284570 benign PTEN hamartoma tumor syndrome 2016-03-31 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000201312 SCV000540135 uncertain significance not specified 2016-03-28 criteria provided, single submitter clinical testing Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Region not covered by ExAC,reported in 1 proband, analysis of patient samples suggests possible impact to PTEN expression, but insufficient evidence for pathogenicity.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.